Unifiedpost’s onboarding of new customers accelerates further in Q3
Growth momentum for digitising SMEs enhances – double digit top line growth
La Hulpe, Belgium – November 10, 2022, 7:00 a.m. CET - Regulated Information - Unifiedpost Group (Euronext: UPG) (Unifiedpost, the Group or the Company) is pleased to announce a continued double-digit digital revenue growth over nine month Interim (9M) 2022 (+16.4%). The recurring digital processing revenue grew by 20% y/y to €83.4 million, while total revenue grew by 13.6% y/y to €135.7 million over the same period. Since the beginning of the year, Unifiedpost grew its customer base by 24.5% to 986,971 SMEs. The onboarding of new customers keeps on accelerating. While in the first six months of the year an average of 19.708 new customers were onboarded per month, this figure has increased to 25.375 on average per month in Q3 2022.
- 9M 2022 Group revenue grew by 13.6% y/y to €135.7 million
- Digital processing revenue grew by more than 16.4% y/y to €88.6 million, with recurring digital processing revenue up 20% The organic growth of digital processing revenue for 9M 2022 was 13.8%
- Strong customer growth of 24.5% compared since the start of the FY 2022
- Growth rates in digital business increasingly supported by European government’s decisions
Commenting on the business update, Hans Leybaert, CEO and founder stated: “We are pleased that the roll-out of our platform is leading to an increased adoption by local entrepreneurs and business owners throughout Europe. During the summer period we saw an increased demand for our solutions resulting in an accelerated customer growth, even though in many markets the digital B2B invoicing is not mandatory today. We put a lot of effort in the geographical expansion of our services throughout Europe, and I’m happy we are succeeding. Our team and solutions prove daily that we are highly scalable: the platform is available in 32 countries, adapted to local needs. During last summer our team for government licence business delivered to the high expectations with the go-live in Serbia. I am proud of the results and the achievements of our Unifiedpost team. We look forward to duplicating this together with our partners for all major licensing deals we have in the pipeline.”
Key financial figures
|(EUR million)||Q3 2022||YTD Q3 2022||YTD Q3 2021||Change (%)|
|Digital processing revenue||29.3||88.6||76.1||+16.4%|
|Recurring digital processing revenue||27.1||83.4||69.5||+20.0%|
|Non-recurring digital revenue||2.2||5.2||6.6||-21.2%|
|Postage & parcel optimisation revenue||14.7||47.1||43.4||+8.5%|
Key business KPI’s
|(#)||End Q3 2022||End Q2 2022||End Q1 2022||End Q4 2021|
|Customers paid by 3rd parties||533,554||480,321||454,819||424.317|
|Companies in business network||2,023,460||1,745,401||1,615,062||1,504,895|
|Organic growth (new subscriptions)||3,928||5,529||5,197||4,855|
|Banqup customers Belgium (Billtobox)||37,459||35,382||31,884||28,864|
|Banqup customers France (JeFacture)||4,087||3,591||2,844||2,072|
Double-digit growth rates in digital processing business
Unifiedpost grew its revenue in the first nine months of 2022 by 13.6% y/y to €135.7 million, driven by strong growth of the recurring digital processing revenue combined with a sound growth in postage and parcel optimisation services.
Growth digital processing mainly driven by organic growth
The Group saw its revenue from digital processing increasing by 16.4% y/y to €88.6 in the first three quarters. 13.8% of the growth was organic. This was mainly driven by the strong growth rate of 20.0% y/y in recurring digital revenue, i.e. digital platform revenue excluding the project and licence business. The growth is spread over different countries and markets, with the Nordic countries, Serbia, Romania, the Baltics, and the Benelux showing growth rates accelerating.
The project and licence business, which is non-recurring, contributed €5.2 million (9M 2021: €6.6m). Because of the guidelines around digital invoicing that are being introduced in more and more European countries, there is an increasing demand from governments for a portal that enables the continuous real-time monitoring of each invoice. This will have a positive impact on the growth that Unifiedpost is pursuing. As indicated with our H1 2022 results, Unifiedpost expects to generate more project and licence revenue by the end of the year as the Company is expected to benefit from significant projects billed in Q4 2022.
96.2% of the total group revenue results from recurring services, in line with Q2 2022.
Sound growth in postage & parcel optimisation business
Group revenue was also supported by robust growth in postage and parcel optimisation services, + 8.5% y/y in 9M 2022 to €47.1 million. Unifiedpost sees its postage and parcel optimisation business having an excellent 9M 2022. The increase in the top-line was caused by the onboarding of large new customers in combination with general price increases.
Customer base grew strongly with improved momentum
Unifiedpost grew its customer base further reaching a new record of 986,971 customers at the end of September (+24.5% compared to YE 2021). The consolidated business network expanded to just above 2 million companies by the end of Q3 2022, representing an estimated 8% of businesses in Europe.
The total number of Banqupcustomers more than doubled since the beginning of FY 2021: from 35,408 YE 2021 to 80,420 at the end of Q3 2022. Banqup is Unifiedpost’s core SME-product allowing customers to create and send sales invoices, keep an overview of all (financial) documents and manage administration. The platform also offers a unique, inhouse developed payment functionality. The customer growth over the last three months includes migration effects from legacy platforms. Adjusting for such migrated users, the number of Banqup users increased by 14,654 in the first nine months of 2022.
Within the French market, Unifiedpost sees the number of JeFacture customers increase steadily. The Unifiedpost management expects the growth rate of its customers in the French market to accelerate in the coming periods.
The overall average revenue per unit (ARPU) in digital processing business1 reached €21.7. The decline in ARPU compared to FY2021 (€27.9) is predominantly due to two effects. The first one is a negative effect from the last quarter as that includes the licence revenue resulting from the project with the Serbian Government. The second one results from the significantly higher and increasing revenue contribution from Unifiedpost’s SME business with a structurally lower ARPU.
Positive cash flow expected for H2 2023
Due to the changed economic circumstances and business conditions, the Company has made the target to become cash flow positive its predominant priority. The target remains to be cash flow positive for H2 2023. <End>
Investors & Media webcast
Management will host a live video webcast for analysts, investors and media today at 10:00 a.m. CET.
A recording will be available shortly after the event. To attend, please register at https://onlinexperiences.com/Launch/QReg/ShowUUID=9B0FAE98-BFBC-42EE-87D6-60C47EAD9555. Participants can also join via telephone. They can obtain their personal dial-in details by registering with this link: https://registrations.events/direct/NTE60150.
A full replay be available after the webcast at: https://www.unifiedpost.com/en/investor-relations
Financial Calendar 2022
- 30 November 2022 Investor Day
Investor Relations & Media
+32 491 15 05 09
About Unifiedpost Group
Unifiedpost is a leading cloud-based platform for SME business services built on “Documents”, “Identity” and “Payments”. Unifiedpost operates and develops a 100% cloud-based platform for administrative and financial services that allows real-time and seamless connections between Unifiedpost’s customers, their suppliers, their customers, and other parties along the financial value chain. With its one-stop-shop solutions, Unifiedpost’s mission is to make administrative and financial processes simple and smart for its customers. Since its founding in 2001, Unifiedpost has grown significantly, expanding to offices in 32 countries, with more than 500 million documents processed in 2021, reaching over 1,600,000 SMEs and more than 2,500 Corporates across its platform today.
Noteworthy facts and figures:
- Established in 2001, with a proven track record
- 2021 turnover €171 million
- 1400+ employees
- Diverse portfolio of clients across a wide variety of industries (banking, leasing, utilities, media, telecommunications, travel, social security service providers, public organisations, etc.) ranging from large internationals to SMEs
- Unifiedpost Payments, a fully owned subsidiary, is recognised as a payment institution by the National Bank of Belgium
- Certified Swift partner
- International M&A track record
- Listed on the regulated market of Euronext Brussels, symbol: UPG
(*) Warning about future statements: The statements contained herein may contain forecasts, future expectations, opinions and other future-oriented statements concerning the expected further performance of Unifiedpost Group on the markets in which it is active. Such future-oriented statements are based on the current insights and assumptions of management concerning future events. They naturally include known and unknown risks, uncertainties and other factors, which seem justified at the time that the statements are made but may possibly turn out to be inaccurate. The actual results, performance or events may differ essentially from the results, performance or events which are expressed or implied in such future-oriented statements. Except where required by the applicable legislation, Unifiedpost Group shall assume no obligation to update, elucidate or improve future-oriented statements in this press release in the light of new information, future events or other elements and shall not be held liable on that account. The reader is warned not to rely unduly on future-oriented statements.
1 Revenue in digital processing revenue divided by number of paying customers at the end of the relevant period.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis11.12.2023 07:15:00 CET | Press release
Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba® (isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration (FDA). Cresemba for injection is approved for adults and now for pediatric patients 1 year of age and older. Cresemba capsules are approved for adults and now for pediatric patients 6 years of age and older, who weigh 16 kilograms and greater. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We congratulate Astellas on the approval of Cresemba for the use in children who suffer from invasive aspergillosis or mucormycosis. These severe mold infections primarily affect children suffering
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)11.12.2023 07:15:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1; the safety profile of iptacopan was consistent with previously reported data1-3 C3 glomerulopathy (C3G) is an ultra-rare complement-mediated kidney disease, with approximately 50% of patients progressing to kidney failure within 10 years of diagnosis4-7; currently no treatments address the underlying cause of C3G7-9 Novartis plans to review results with global health authorities to enable potential submissions in 2024; data will be submitted for presentation at an upcoming medical meeting Iptacopan demonstrated positive Phase III results in IgA nephropathy (IgAN) at the interim analysis and a late-stage development program is ongoing across four investigational indications10-14 Basel, December 11, 2023 — Novartis today announced positive topline results from the six-month, double-blind period
Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs11.12.2023 07:00:00 CET | Press release
Press Release Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs Memorandum of understanding covers the utilization of Nokia’s Network as Code platform and developer portal with BT Group’s cloud-native network 11 December 2023 Espoo, Finland – Nokia and BT Group today announced an agreement to develop new 5G network monetization opportunities through Nokia’s Network as Code platform with developer portal (platform) and BT Group’s cloud-native network. BT Group, which operates EE – the UK’s best mobile network1 – is, like other communications service providers, looking to Nokia’s growing ecosystem of developer partners to gain access to simplified network capabilities in the form of software code that can be built into applications for enterprise, industrial, and consumer use cases. The Nokia platform helps operators monetize their 5G network assets beyond pure connectivity. It provides application developers with tools such as Software Devel
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma11.12.2023 07:00:00 CET | Press release
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, 9-12 December 2023. Based on 32-month and 3-year follow-ups of two pivotal studies for fixed-duration treatments of Columvi® (glofitamab) and Lunsumio® (mosunetuzumab), respectively, data show that remissions were maintained in the majority of patients with heavily pre-treated lymphomas.1,2 Additionally, new early-phase data of novel Columvi or Lunsumio combination regimens support o
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone11.12.2023 01:30:59 CET | Press release
Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone Phase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10-5MRD negativity rate measured at a sensitivity of 10-6 was 67% for Sarclisa combination therapyResults shared during oral presentation at ASH 2023 plenary scientific session PARIS, December 10, 2023. The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidatio